Gemcitabine treatment of pancreatic cancer peritonitis

Japanese Journal of Gastroenterology

Volumn 100, Issue 1, 2003, Pages 73-78

  Horiki, Noriyuki ^a   Maruyama, Masataka ^a   Fujita, Yoshiyuki ^a   Suzuki, Yuko ^a   Tanaka, Tsuyoshi ^a   Shimomura, Makoto ^a   Tanigawa, Kanji ^a   Sasaki, Hidehito ^a   Fujiwara, Mieko ^a   Suzuki, Kouyou ^a   Imoto, Ichiro ^a   Adachi, Yukihiko ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; GEMCITABINE;

AGED; ARTICLE; CANCER THERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; MALE; PANCREAS CANCER; PERITONITIS;

EID: 0037239053     PISSN: 04466586     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Parker ST, Tong T, Bold S, et al: Cancer statistics. CV Cancer Clin 1997; 47: 5-27
2. Wanebo HJ, Vezeridis MP: Pancreatic carcinoma in perspective: a continuing challenge. Cancer 1996; 78: 580-591
3. (gemcitabine hydrochloride) 2001; 28: 1461-1467
4. Hawes HR, Xiong Q, Waxman I, et al: A multispecialty approach to the diagnosis and management of pancreatic cancer. Am J gastroenterol 2000; 95: 17-31
5. rd, Moore MJ, Andresen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413
6. Casper ES, Green MR, Kelsen DP, et al: Phase II trial of gemcitabine (2, 2′-difluorodeoxycytidine) in patients with adenocarcinoma of pancreas. Inves New Drugs 1994; 12: 29-34
7. Carmichael J, Fink U, Russell RCG, et al: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J cancer 1996; 73: 101-105
8. Kurtz JE, Lenoir VT, Bugat R, et al: Compassionate use of gemcitabine in advanced pancreatic cancer: a french multicentric study. Bull Cancer 1999; 86: 202-206
9. Crino L, Mosconi AM, Calandri C, et al: Gemcitabine in advanced pancreatic cancer. A phase II trial. Am J Clin Oncol 2001; 24: 296-298
10. Okada S, Ueno H, Okusaka T, et al: Phase I trial of gemcitabine in patients with advanced pancreatic cancer. Jpn J Clin Oncol 2001; 31: 7-12
11. Rothenberg ML, Moore MJ, Cripps MC, et al: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996; 7: 347-353
12. Halm U, Schumann T, Schiefke I, et al: Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 2000; 82: 1013-1016
13. Isokangas PO, Knuuttila A, Halme M, et al: Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer. Ann Oncol 1999; 10: 1059-1063
14. Rinaldi AD, Lormand AN, Brierre EJ, et al: A phase I trail of gemcitabine and infusional 5-FU in patients with refractory solid tumors. Am J Clin Oncol 2000; 23: 78-82
15. Gertler SZ, MacDonald D, Goodyear M, et al: NCIC-CTG phase II study of gemcitabine in patients with malignant glioma. Ann Oncol 2000; 11: 315-318
16. Okada S: Non-surgical treatment of pancreatic cancer. Int J Clin Oncol 1999; 4: 257-266
17. Wolff AR, Evans BD, Gravel MD, et al: Phase I trail of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 2001; 7: 2246-2253
18. McGinn C, Zalupski MM, Shureiqi I, et al: Phase I trail of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001; 19: 4202-4208
19. Heinemann V, Wilke H, Mergenthaler HG, et al: Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 2000; 11: 1399-1403
20. Philip P, Zalupski Mark, Vaitkevicius, et al: Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 2001; 92: 569-577
21. Colucci G, Giuliani F, Gebbia V, et al: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma. Cancer 2002; 94: 904-910